Medical Conference Schedule Sept. 2013 through March 2014

Biopharma Reaches 50% Enrollment in New ALS Drug Program
Source: Jason Kolbert (02/02/2026)

MediciNova Inc. (MNOV:NASDAQ) enrolls 100 patients in the SEANOBI Expanded Access Program for MN-166 (ibudilast), noted a D. Boral Capital report. Read on to learn the many potential catalysts ahead for this California-based firm.

read more >

Drug Developer Uncovers Excellent Progress in 200-Patient ALS Study
Source: Streetwise Reports (02/02/2026)

Biopharmaceutical company MediciNova Inc. (MNOV:NASDAQ) announces that by the end of January, 12 sites in the U.S. have been activated and 100 patients have been enrolled in its studying evaluating its treatment for ALS. Read what one analyst says investors should be looking for from the company in the coming year.

read more >

Biopharmaceutical Co. Looking for Breakthrough in US$987.6M ALS Treatment Market
Source: Streetwise Reports (01/30/2026)

Biopharmaceutical firm MediciNova Inc. (MNOV:NASDAQ) reports that by the end of January, it has activated 12 sites in the U.S. and enrolled 100 patients in its study assessing its ALS treatment. Discover what one analyst suggests investors should watch for from the company in the upcoming year.

read more >

Clean Tech Developer Sees Massive Opportunity in PFAS Treatment
Source: Streetwise Reports (01/29/2026)

BioLargo Inc. (BLGO:OTCQX) announces that its patented Aqueous Electrostatic Concentrator (AEC) PFAS treatment system has been installed in New Jersey. Find out why the company sees massive upside for its products.

read more >

Environmental Firm Finds High-Value Position in PFAS Remediation Industry
Source: Streetwise Reports (01/28/2026)

BioLargo Inc. (BLGO:OTCQX) has announced the installation of its patented Aqueous Electrostatic Concentrator (AEC) PFAS treatment system in New Jersey. Discover why the company anticipates significant potential for its products.

read more >